- North America
- United States
- Service category
- Formulation development and drug delivery
Your company? Get access to this profile.
Jennerex, Inc. is a private, clinical-stage biotherapeutics company focused on the design, development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for cancer. Our lead product JX-594 is currently in a randomized Phase 2b clinical trial for hepatocellular carcinoma (HCC) and Phase 1/2 clinical development for colorectal cancer (CRC). A 30-patient, randomized, controlled Phase 2 clinical trial of JX-594 in advanced HCC showed a statistically significant, dose-dependent increase in overall survival for high-dose JX-594 versus low-dose JX-594. Clinical trials of JX-594 using both intratumoral and intravenous administration are being conducted in multiple tumor types.
Pictures of this company
You might also be interested in
Sourcing this company's services?Send inquiry anonymously »